MCID: SRC014
MIFTS: 66

Sarcoma malady

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Sarcoma

Aliases & Descriptions for Sarcoma:

Name: Sarcoma 12 29 52 14 69
Connective and Soft Tissue Neoplasm 12
Tumor of Soft Tissue and Skeleton 12
Sarcoma - Category 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1115
ICD10 33 C49
ICD9CM 35 171 171.9
SNOMED-CT 64 187985009 93765001
UMLS 69 C0153519

Summaries for Sarcoma

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Sarcoma, also known as connective and soft tissue neoplasm, is related to mediastinum sarcoma and kaposi sarcoma. An important gene associated with Sarcoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Developmental Biology and Cytokine Signaling in Immune system. The drugs Doxil and Fusilev have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and kidney, and related phenotypes are Decreased substrate adherent cell growth and integument

Wikipedia : 71 A sarcoma (plural sarcomas or sarcomata; from the Greek σάρξ sarx meaning \"flesh\") is a cancer... more...

Related Diseases for Sarcoma

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 793)
id Related Disease Score Top Affiliating Genes
1 mediastinum sarcoma 32.8 ASPSCR1 EWSR1 KIT
2 kaposi sarcoma 12.5
3 ewing sarcoma 12.3
4 follicular dendritic cell sarcoma 12.2
5 alveolar soft-part sarcoma 12.2
6 myeloid sarcoma 12.2
7 endometrial stromal sarcoma 12.2
8 soft tissue sarcoma 12.2
9 epithelioid sarcoma 12.1
10 langerhans cell sarcoma 12.1
11 clear cell sarcoma 12.1
12 mast-cell sarcoma 12.1
13 interdigitating dendritic cell sarcoma 12.1
14 sarcoma, synovial 12.1
15 histiocytic sarcoma 12.1
16 spindle cell sarcoma 12.1
17 paraganglioma and gastric stromal sarcoma 12.0
18 uterine sarcoma 12.0
19 undifferentiated pleomorphic sarcoma 12.0
20 prostate stromal sarcoma 12.0
21 retroperitoneal sarcoma 12.0
22 bladder sarcoma 12.0
23 heart sarcoma 12.0
24 kidney clear cell sarcoma 12.0
25 liver sarcoma 12.0
26 esophagus sarcoma 11.9
27 gallbladder sarcoma 11.9
28 reticulum cell sarcoma 11.9
29 bone ewing's sarcoma 11.9
30 small intestinal sarcoma 11.8
31 mediastinum synovial sarcoma 11.8
32 vulvar alveolar soft part sarcoma 11.8
33 extraosseous ewing's sarcoma 11.8
34 rectum sarcoma 11.8
35 trachea sarcoma 11.8
36 colon kaposi sarcoma 11.8
37 paranasal sinus sarcoma 11.8
38 rectum kaposi's sarcoma 11.8
39 biphasic synovial sarcoma 11.8
40 meninges sarcoma 11.8
41 kidney sarcoma 11.8
42 monophasic synovial sarcoma 11.8
43 cervical alveolar soft part sarcoma 11.8
44 penis sarcoma 11.8
45 testis sarcoma 11.8
46 kidney osteogenic sarcoma 11.8
47 bile duct sarcoma 11.8
48 anus sarcoma 11.8
49 breast sarcoma 11.8
50 spindle cell synovial sarcoma 11.8

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to Sarcoma

Symptoms & Phenotypes for Sarcoma

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 10.21 KIT FES
2 Decreased substrate adherent cell growth GR00193-A-2 10.21 KIT YES1 FES MOS
3 Decreased substrate adherent cell growth GR00193-A-3 10.21 YES1 MOS BRAF
4 Decreased substrate adherent cell growth GR00193-A-4 10.21 KIT YES1 BRAF
5 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.81 SSX2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.81 BRAF
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.81 SSX1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.81 SSX3 SSX5 BRAF SSX1 SSX2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.81 BRAF
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.81 BRAF
11 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.81 BRAF
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.81 SSX3 SSX5
13 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.81 SSX1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.81 BRAF
15 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.81 SSX2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.81 BRAF
17 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.81 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.81 SSX3 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.81 SSX5
20 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.81 SSX5
21 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.81 SSX1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.81 SSX1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.81 SSX5
24 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.81 SSX3 SSX2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.81 SSX3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.81 SSX2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.81 SSX5
28 Increased shRNA abundance (Z-score > 2) GR00366-A-92 9.81 SSX3
29 Decreased cell migration GR00055-A-1 9.8 LYN YES1 BRAF CRK FES HRAS
30 Decreased viability in HMC1.1 cells GR00105-A-0 9.33 KIT LYN SRC
31 Increased cell viability after pRB stimulation GR00230-A-1 9.26 FES KIT MOS YES1

MGI Mouse Phenotypes related to Sarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.86 BRAF FES HRAS JUN KIT LYN
2 neoplasm MP:0002006 9.7 BRAF FES FLI1 HRAS KIT MOS
3 nervous system MP:0003631 9.7 BRAF CRK FES FLI1 HRAS JUN
4 respiratory system MP:0005388 9.23 YES1 BRAF CRK HRAS JUN KIT

Drugs & Therapeutics for Sarcoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
2
Fusilev 17 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals Approved March of 2008
3
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
4
Taxol 17 46 PACLITAXEL Bristol-Myers Squibb Approved August 1997
5
Votrient 17 46 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline Approved April 2012/ Approved October of 2009

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 596)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
5
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
6
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
7
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
8
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
9
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
10
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
11
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
12
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
13
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
14
Tenofovir Approved, Investigational Phase 4,Phase 3 147127-20-6 464205
15
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 1 154361-50-9 60953
16
Ethiodized oil Approved Phase 4 8008-53-5
17
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
18 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Vaccines Phase 4,Phase 1,Phase 2
26 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
29 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
35 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
36 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
37 Antibodies Phase 4,Phase 3,Phase 1,Phase 2
38 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2
39 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2
40 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
41 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
42 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
43 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
44 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
45 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
47 Antidepressive Agents Phase 4
48 Antimanic Agents Phase 4,Phase 1,Phase 2
49 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
50 Lithium carbonate Phase 4 554-13-2

Interventional clinical trials:

(show top 50) (show all 1602)
id Name Status NCT ID Phase
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4
4 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4
5 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4
6 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
7 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
8 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4
9 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4
10 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
11 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Not yet recruiting NCT03144206 Phase 4
12 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Not yet recruiting NCT02625389 Phase 4
13 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3
14 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3
15 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
16 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735 Phase 3
17 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3
18 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3
19 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
20 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3
21 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3
22 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
23 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
24 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3
25 Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor Unknown status NCT00103168 Phase 3
26 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3
27 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3
28 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
29 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3
30 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3
31 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3
32 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3
33 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3
34 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
35 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3
36 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
37 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3
38 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
39 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
40 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3
41 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3
42 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3
43 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3
44 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3
45 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3
46 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3
47 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3
48 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3
49 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3
50 Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy Completed NCT00283582 Phase 3

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Sarcoma

Genetic tests related to Sarcoma:

id Genetic test Affiliating Genes
1 Sarcoma 29

Anatomical Context for Sarcoma

MalaCards organs/tissues related to Sarcoma:

39
Myeloid, Bone, Kidney, Liver, Breast, Lung, Endothelial

Publications for Sarcoma

Articles related to Sarcoma:

(show top 50) (show all 8999)
id Title Authors Year
1
Surveillance Imaging Patterns and Outcomes Following Radiation Therapy and Radical Resection for Localized Extremity and Trunk Soft Tissue Sarcoma. ( 28058559 )
2017
2
Ewing sarcoma of the sternal manubrium: first report of a case in Australasia and review of the literature. ( 28419662 )
2017
3
Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. ( 28417551 )
2017
4
Treatment of soft tissue sarcoma: a focus on earlier stages. ( 27918202 )
2017
5
Alveolar soft part sarcoma with brain metastases. ( 28413551 )
2017
6
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. ( 27696380 )
2017
7
Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. ( 28439237 )
2017
8
Imaging investigations before referral to a sarcoma center delay the final diagnosis of musculoskeletal sarcoma. ( 28077058 )
2017
9
Surgical management and outcome of spinal alveolar soft part sarcoma (ASPA): a case series of five patients and literature review. ( 28166791 )
2017
10
CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma. ( 28404587 )
2017
11
DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. ( 27894957 )
2017
12
Laryngeal alveolar soft part sarcoma: A case report of a rare malignancy in an atypical location. ( 28131550 )
2017
13
Acral pseudolymphomatous angiokeratoma of children with rainbow pattern: A mimicker of Kaposi sarcoma. ( 28087020 )
2017
14
Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma. ( 28291905 )
2017
15
Is acquired arterial-venous fistula related to Kaposi sarcoma? ( 28214029 )
2017
16
Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial. ( 28436593 )
2017
17
Perilipin 1 is a highly specific marker for adipocytic differentiation in sarcomas with intermediate sensitivity. ( 27646609 )
2017
18
Extra-skeletal Ewing sarcoma of the lumbosacral region in an adult pregnant patient: a case report. ( 28435928 )
2017
19
Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition. ( 28424322 )
2017
20
Alveolar soft-part sarcoma of the mediastinum: A case report. ( 28321306 )
2017
21
Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. ( 28429277 )
2017
22
RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. ( 28046107 )
2017
23
Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. ( 28477025 )
2017
24
Recombinant parvoviruses armed to deliver CXCL4L1 and CXCL10 are impaired in their antiangiogenic and antitumoral effects in a Kaposi sarcoma tumor model due to the chemokines' interference with the virus cycle. ( 28042949 )
2017
25
Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. ( 28045549 )
2017
26
Kaposi sarcoma, oral malformations, mitral dysplasia, and scoliosis associated with 7q34-q36.3 heterozygous terminal deletion. ( 28488400 )
2017
27
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma. ( 28067691 )
2017
28
Bone adaptation of a biologically reconstructed femur after Ewing sarcoma: Long-term morphological and densitometric evolution. ( 28447127 )
2017
29
Hepatic Kaposi sarcoma: A case report and review of the literature. ( 28217255 )
2017
30
The importance of treating by histological subtype in advanced soft tissue sarcoma. ( 27918201 )
2017
31
Kaposi Sarcoma in a patient treated with Ruxolitinib. ( 28419187 )
2017
32
Antia89proliferative activity of epigallocatechina893a89gallate and silibinin on soft tissue sarcoma cells. ( 27909727 )
2017
33
Inadvertently boarding a pirate ship: disease progression in a paediatric patient with relapsed metastatic Ewing sarcoma receiving treatment at a centre for alternative therapy in Mexico. ( 28062429 )
2017
34
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. ( 28085948 )
2017
35
Kaposi Sarcoma and Lung Transplant: Two Case Reports. ( 28501344 )
2017
36
Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency. ( 28430817 )
2017
37
Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma. ( 27923328 )
2017
38
Primary Bone Anaplastic Large Cell Lymphoma Masquerading as Ewing Sarcoma: Diagnosis by Anchored Multiplex PCR. ( 28452858 )
2017
39
Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. ( 28394855 )
2017
40
Primary Ewing sarcoma of the kidney: a case report and treatment review. ( 28509141 )
2017
41
Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. ( 28355116 )
2017
42
Ewing Sarcoma and Atypical Teratoid Rhabdoid Tumor. ( 28382842 )
2017
43
Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet Laser: A Preliminary Study. ( 28157730 )
2017
44
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. ( 27900663 )
2017
45
Pulmonary Kaposi Sarcoma with Osseous Metastases in an Human Immunodeficiency Virus (HIV) Patient: A Remarkable Response to Highly Active Antiretroviral Therapy. ( 28216610 )
2017
46
The Significant Effects of Pazopanib on Multiple Pulmonary Metastatic Lesions of Alveolar Soft Part Sarcoma: A Case Report. ( 28060129 )
2017
47
Evolution in soft tissue sarcoma. ( 27918200 )
2017
48
Classic Kaposi sarcoma in an HIV-negative Han Chinese man: a case report. ( 28329475 )
2017
49
MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients. ( 28083704 )
2017
50
Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. ( 28068242 )
2017

Variations for Sarcoma

ClinVar genetic disease variations for Sarcoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091

Expression for Sarcoma

Search GEO for disease gene expression data for Sarcoma.

Pathways for Sarcoma

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 BRAF FES HRAS JUN KIT LYN
2
Show member pathways
13.39 BRAF CRK HRAS KIT LYN SRC
3
Show member pathways
12.92 BRAF HRAS JUN KIT LYN SRC
4
Show member pathways
12.89 BRAF CRK HRAS JUN LYN SRC
5
Show member pathways
12.86 BRAF CRK HRAS LYN SRC YES1
6
Show member pathways
12.82 BRAF CRK HRAS JUN SRC
7
Show member pathways
12.81 BRAF CRK HRAS JUN SRC
8
Show member pathways
12.75 BRAF CRK HRAS KIT SRC
9 12.74 BRAF CRK HRAS JUN MOS
10 12.69 BRAF CRK HRAS JUN KIT
11 12.64 BRAF CRK HRAS MOS SRC
12
Show member pathways
12.4 BRAF CRK HRAS JUN LYN
13
Show member pathways
12.39 BRAF HRAS JUN SRC
14
Show member pathways
12.37 BRAF HRAS JUN KIT SRC
15
Show member pathways
12.35 BRAF CRK HRAS JUN SRC YES1
16
Show member pathways
12.31 CRK LYN SRC YES1
17 12.31 HRAS JUN LYN SRC
18
Show member pathways
12.31 BRAF CRK HRAS JUN SRC
19
Show member pathways
12.28 BRAF HRAS JUN SRC
20
Show member pathways
12.24 HRAS LYN SRC YES1
21
Show member pathways
12.18 BRAF CRK HRAS JUN SRC YES1
22
Show member pathways
12.16 BRAF CRK HRAS JUN
23 12.16 BRAF CRK HRAS JUN SRC
24
Show member pathways
12.12 CRK HRAS JUN KIT LYN SRC
25
Show member pathways
12.01 CRK LYN SRC YES1
26 11.97 BRAF HRAS JUN SRC
27 11.95 CRK FES KIT LYN SRC YES1
28
Show member pathways
11.91 FES HRAS LYN SRC
29
Show member pathways
11.88 FES HRAS SRC YES1
30 11.84 HRAS LYN SRC YES1
31 11.83 BRAF JUN SRC
32
Show member pathways
11.8 BRAF HRAS JUN KIT
33 11.76 CRK LYN SRC YES1
34 11.75 BRAF HRAS SRC
35 11.69 HRAS JUN SRC
36
Show member pathways
11.69 BRAF HRAS SRC
37 11.69 BRAF HRAS JUN SRC
38 11.65 BRAF HRAS LYN
39
Show member pathways
11.64 BRAF FES SRC
40
Show member pathways
11.62 LYN SRC YES1
41 11.61 HRAS JUN SRC
42 11.58 CRK HRAS JUN LYN SRC
43 11.57 HRAS LYN SRC YES1
44 11.55 CRK HRAS JUN SRC
45 11.54 LYN SRC YES1
46 11.51 CRK LYN SRC YES1
47 11.5 LYN SRC YES1
48 11.49 CRK HRAS JUN
49 11.47 BRAF HRAS JUN LYN SRC YES1
50 11.45 LYN SRC YES1

GO Terms for Sarcoma

Cellular components related to Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 ASPSCR1 BRAF CRK EWSR1 FLI1 FUS
2 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 8.92 FES LYN SRC YES1

Biological processes related to Sarcoma according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.98 BRAF FES KIT LYN MOS SRC
2 protein phosphorylation GO:0006468 9.95 BRAF FES KIT LYN MOS SRC
3 MAPK cascade GO:0000165 9.93 BRAF HRAS KIT MOS
4 intracellular signal transduction GO:0035556 9.93 BRAF KIT LYN MOS SRC SS18
5 leukocyte migration GO:0050900 9.89 HRAS LYN SRC YES1
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.86 BRAF HRAS JUN SRC
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 LYN SRC YES1
8 Fc-gamma receptor signaling pathway involved in phagocytosis GO:0038096 9.8 CRK LYN SRC YES1
9 positive regulation of MAPK cascade GO:0043410 9.79 HRAS KIT MOS
10 T cell costimulation GO:0031295 9.79 LYN SRC YES1
11 peptidyl-tyrosine phosphorylation GO:0018108 9.77 FES KIT LYN SRC YES1
12 cellular response to transforming growth factor beta stimulus GO:0071560 9.76 CRK SRC YES1
13 positive regulation of MAP kinase activity GO:0043406 9.75 HRAS KIT SRC
14 epidermal growth factor receptor signaling pathway GO:0007173 9.74 FES HRAS SRC
15 response to hydrogen peroxide GO:0042542 9.72 CRK JUN SRC
16 cellular response to calcium ion GO:0071277 9.71 BRAF FUS JUN
17 activation of MAPKK activity GO:0000186 9.69 BRAF CRK MOS
18 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.65 KIT LYN SRC
19 positive regulation of actin cytoskeleton reorganization GO:2000251 9.63 FES HRAS
20 regulation of cell proliferation GO:0042127 9.63 BRAF FES JUN KIT SRC YES1
21 negative regulation of nucleic acid-templated transcription GO:1903507 9.62 SSX1 SSX2 SSX3 SSX5
22 regulation of vascular permeability GO:0043114 9.61 SRC YES1
23 regulation of mast cell degranulation GO:0043304 9.6 FES LYN
24 peptidyl-tyrosine autophosphorylation GO:0038083 9.56 FES LYN SRC YES1
25 myeloid progenitor cell differentiation GO:0002318 9.52 BRAF KIT
26 protein autophosphorylation GO:0046777 9.43 FES KIT LYN MOS SRC YES1
27 ephrin receptor signaling pathway GO:0048013 9.1 CRK HRAS LYN SRC SS18 YES1

Molecular functions related to Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleic acid binding GO:0003676 9.93 EWSR1 FUS SSX1 SSX2 SSX3 SSX5
2 kinase activity GO:0016301 9.87 BRAF FES KIT LYN MOS SRC
3 enzyme binding GO:0019899 9.77 CRK JUN LYN SRC YES1
4 transcription corepressor activity GO:0003714 9.71 SSX1 SSX2 SSX3 SSX5
5 protein tyrosine kinase activity GO:0004713 9.65 FES KIT LYN SRC YES1
6 protein kinase activity GO:0004672 9.5 BRAF FES KIT LYN MOS SRC
7 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.43 KIT LYN
8 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.92 FES LYN SRC YES1
9 protein binding GO:0005515 10.13 ASPSCR1 BRAF CRK EWSR1 FES FLI1

Sources for Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....